NCT03077217View on ClinicalTrials.gov

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Covert Hepatic Encephalopathy
Interventions
DRUG

Rifaximin

The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy

Trial Locations (1)

200003

Shanghai changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER

NCT03077217 - Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter